Curacell develops cell based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.
The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact on cancer patients worldwide.
StromaBio is a clinical stage biopharma company building on more than two decades of research on mesenchymal stromal cells (MSC).
The company has a broad pipeline based on its own product application and is a leader in the field of neurology and acute inflammatory diseases.
Cellavos develops innovative treatments for horses based on mesenchymal stromal cells (MSC) for a range of chronic diseases.
Cellavos has treated more than 300 horses in pre-clinical studies and is developing clinical programs based on both MSCs from donor horses and extracellular vesicles (EV).
Cellcolabs is a biotech impact start-up specializing in industrial GMP production of high quality stem cells (mesenchymal stromal cells) in order to make them available at scale.
Cellcolab’s goal is to accelerate stem cell research and make the treatments of the future available for all.